Abstract: Cutaneous T-cell lymphomas (CTCLs) are a rare group of lymphoproliferative diseases. The therapeutic options vary in the types of CTCL and disease stages. Most subtypes of CTCL present with an indolent course and slow progression, such as early mycosis fungoides (MF) and lymphomatoid papulosisis, which may be well controlled by topical skin-targeted therapies. For the patients with highly aggressive or refractory disease (Sézary syndrome, relapsed CTCL), systemic therapies including chemotherapy are often applied. In this article, the current and new emerging treatment strategies for CTCL are reviewed.

Key words: CTCL, immunomodulatory agents, targeted therapy